Pemphigus Overview

Save information for later
Sign Up

Learn About Pemphigus

What is the definition of Pemphigus?
Pemphigus is a group of rare autoimmune diseases that cause blistering of the skin and mucous membranes (mouth, nose, throat, eyes, and genitals). This condition can occur at any age, but often strikes people in middle or older age. Studies have shown that some populations may be at greater risk for certain types of Pemphigus. For instance, people of Jewish descent and those from India, Southeast Europe, and the Middle East are at greater risk for Pemphigus vulargis, while Pemphigus foliaceus is more common in North America, Turkey, and South America.
What are the alternative names for Pemphigus?
  • Pemphigus
Who are the top Pemphigus Local Doctors?
Victoria P. Werth
Elite in Pemphigus
Dr. Victoria P. Werth
Dermatology
Elite in Pemphigus
Dr. Victoria P. Werth
Dermatology

Penn Dermatology Perelman

3400 Civic Center Boulevard, South Pavilion, 1st Floor, 
Philadelphia, PA 
215-662-2737
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Victoria Werth is a Dermatologist in Philadelphia, Pennsylvania. Dr. Werth is rated as an Elite provider by MediFind in the treatment of Pemphigus. Her top areas of expertise are Cutaneous Lupus Erythematosus (CLE), Dermatomyositis, Discoid Lupus Erythematosus (DLE), and Pemphigus. Dr. Werth is currently accepting new patients.

Ron J. Feldman
Elite in Pemphigus
Dr. Ron J. Feldman
Dermatology
Elite in Pemphigus
Dr. Ron J. Feldman
Dermatology

Emory Clinic At 1525 Clifton Road

1525 Clifton Road Northeast, Fl3, 
Atlanta, GA 
404-778-3333
Experience:
20+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Ron Feldman is a Dermatologist in Atlanta, Georgia. Dr. Feldman has been practicing medicine for over 20 years and is rated as an Elite provider by MediFind in the treatment of Pemphigus. His top areas of expertise are Pemphigus Foliaceus, Pemphigus, Bullous Pemphigoid, and Pemphigus Vulgaris.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Pemphigus
Dr. Christoph T. Ellebrecht
Dermatology
Elite in Pemphigus
Dr. Christoph T. Ellebrecht
Dermatology

Penn Dermatology Perelman

3400 Civic Center Boulevard, South Pavilion, 1st Floor, 
Philadelphia, PA 
215-662-2737
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Christoph Ellebrecht is a Dermatologist in Philadelphia, Pennsylvania. Dr. Ellebrecht is rated as an Elite provider by MediFind in the treatment of Pemphigus. His top areas of expertise are Pemphigus, Pemphigus Vulgaris, Pemphigus Foliaceus, and Bullous Pemphigoid. Dr. Ellebrecht is currently accepting new patients.

View All Doctors
What are the latest Pemphigus Clinical Trials?
ONO-4059-10:Multicenter, Placebo-controlled, Randomized, Double-blind, Phase 3 Study in Patients With Steroid-resistant Pemphigus (BRILLIANT Study)
ONO-4059-10:Multicenter, Placebo-controlled, Randomized, Double-blind, Phase 3 Study in Patients With Steroid-resistant Pemphigus (BRILLIANT Study)
Enrollment Status: Recruiting
Publish Date: July 22, 2025
Intervention Type: Drug
Study Phase: Phase 3

Summary: ONO-4059-10:Multicenter, placebo-controlled, randomized, double-blind, Phase 3 study in patients with steroid-resistant pemphigus

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris
A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris
Who is this study for: Adult patients with Mucosal-Dominant Pemphigus Vulgaris
Enrollment Status: Recruiting
Publish Date: March 17, 2025
Intervention Type: Biological
Study Drug: Autologous Desmoglein 3 CAR-T Cells
Study Phase: Phase 1

Summary: A phase 1/2, open-label, safety and dosing study of autologous CART cells (desmoglein 3 chimeric autoantibody receptor T cells \[DSG3-CAART\] or CD19-specific Chimeric Antigen Receptor T cells \[CABA-201\]) in subjects with active, pemphigus vulgaris

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center